CoChat

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone

Open access
Agarwal, Rajiv, Anker, Stefan D, Bakris, George, Filippatos, Gerasimos, Pitt, Bertram, Rossing, Peter, Ruilope, Luis, Gebel, Martin, Kolkhof, Peter, Nowack, Christina, Joseph, Amer, on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators · 2022 · Nephrology Dialysis Transplantation

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Despite the standard of care, patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) progress to dialysis, are hospitalized for heart failure and die prematurely. Overactivation of the mineralocorticoid receptor (MR) causes inflammation and fibrosis that damages the kidney and heart. Finerenone, a nonsteroidal, selective MR antagonist, confers kidney and heart protection in both animal models and Phase II clinical studies; the effects on serum potassium and kidney function are minimal. Comprising the largest CKD outcomes program to date, FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) and FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease) are Phase III trials investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes from early to advanced CKD in T2D. By including echocardiograms and biomarkers, they extend our understanding of pathophysiology; by including quality of life measurements, they provide patient-centered outcomes; and by including understudied yet high-risk cardiorenal subpopulations, they have the potential to widen the scope of therapy in T2D with CKD. Trial registration number: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfaa294

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Schematic representation of the pathophysiological effects of MR overactivation and the subsequent impact of MRA intervention using finerenone or spironolactone. K+, potassium; Na+, sodium
FIGURE 1 Schematic representation of the pathophysiological effects of MR overactivation and the subsequent impact of MRA intervention using finerenone or spironolactone. K+, potassium; Na+, sodiumCC BY-NC · PubMed Central
FIGURE 2 Percentage of patients with a treatment-emergent adverse event of hyperkalemia defined as serum potassium ≥5.6 mEq/L in Phase II finerenone trials. Data are point estimates ± 95% CIs. eple: eplerenone; F: finerenone; HFrEF: heart failure with reserved ejection fraction; spiro: spironolactone.
FIGURE 2 Percentage of patients with a treatment-emergent adverse event of hyperkalemia defined as serum potassium ≥5.6 mEq/L in Phase II finerenone trials. Data are point estimates ± 95% CIs. eple: eplerenone; F: finerenone; HFrEF: heart failure with reserved ejection fraction; spiro: spironolactone.CC BY-NC · PubMed Central
FIGURE 3 FIDELIO-DKD and FIGARO-DKD endpoints. aKidney failure defined as occurrence of ESKD (initiation of chronic dialysis for ≥90 days or renal transplantation) or sustained eGFR <15 mL/min/1.73 m2. HF: heart failure; HRQoL: health-related quality of life; MI: myocardial infarction.
FIGURE 3 FIDELIO-DKD and FIGARO-DKD endpoints. aKidney failure defined as occurrence of ESKD (initiation of chronic dialysis for ≥90 days or renal transplantation) or sustained eGFR <15 mL/min/1.73 m2. HF: heart failure; HRQoL: health-related quality of life; MI: myocardial infarction.CC BY-NC · PubMed Central
FIGURE 4 (A) Overlap of patient populations according to inclusion values for UACR and eGFR in the FIDELIO-DKD and the FIGARO-DKD trials. (B) Pooled data showing the baseline KDIGO risk categories of patients included in the FIDELIO-DKD and FIGARO-DKD trials (KDIGO score risk category data were missing for 4 patients in the FIDELIO-DKD trial and 10 patients in the FIGARO-DKD trial). Values are presented as n (%).
FIGURE 4 (A) Overlap of patient populations according to inclusion values for UACR and eGFR in the FIDELIO-DKD and the FIGARO-DKD trials. (B) Pooled data showing the baseline KDIGO risk categories of patients included in the FIDELIO-DKD and FIGARO-DKD trials (KDIGO score risk category data were missing for 4 patients in the FIDELIO-DKD trial and 10 patients in the FIGARO-DKD trial). Values are presented as n (%).CC BY-NC · PubMed Central
FIGURE 5. Comparison of baseline median UACR (mg/g) and mean eGFR (mL/min/1.73 m2) of patients enrolled in recent trials investigating cardiovascular and/or renal outcomes in patients with CKD in T2D (circle sizes are proportional to the population sizes of the trials.) [12, 14, 43–49].
FIGURE 5. Comparison of baseline median UACR (mg/g) and mean eGFR (mL/min/1.73 m2) of patients enrolled in recent trials investigating cardiovascular and/or renal outcomes in patients with CKD in T2D (circle sizes are proportional to the population sizes of the trials.) [12, 14, 43–49].CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 2

  1. International Diabetes Federation, 2019, IDF Diabetes Atlas
  2. Pavkov, 2018, Diabetes in America

Cited by

See all 104

Metadata

Authors
Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., Joseph, A., & on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators
Affiliations
  • Richard L. Roudebush VA Medical Center (US)
  • German Centre for Cardiovascular Research (DE)
  • University of Chicago (US)
  • National and Kapodistrian University of Athens (GR)
  • University of Michigan (US)
  • University of Copenhagen (DK)
  • Hospital Universitario 12 De Octubre (ES)
  • Bayer (Germany) (DE)
Corresponding author
Agarwal, Rajiv
Venue
Nephrology Dialysis Transplantation
Published
2020-12-06
Volume
37
Issue
6
Pages
1014-1023
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W3110972804
Cited by
103
References
44
Citations by year
2026: 8 · 2025: 12 · 2024: 28 · 2023: 23 · 2022: 17 · 2021: 15
FWCI
8.94
Type
journal article
Language
en
Open access
Locations
  • Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
  • ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, cc-by-nc-nd)
  • ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
Funders
Bayer AG
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
finerenone, chronic kidney disease, type 2 diabetes, mineralocorticoid receptor antagonists, diabetic nephropathy, renal failure, cardiovascular outcomes, FIDELIO-DKD, FIGARO-DKD, heart failure, renal fibrosis, quality of life
MeSH terms
Mineralocorticoid Receptor Antagonists, Animals, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Renal Dialysis, Humans, Naphthyridines, Quality of Life, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. https://app.cochat.ai/papers/10.1093/ndt/gfaa294
The paper
Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., Joseph, A., & on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators. (2022). Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaa294

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.